Wrap Text
Notification: transactions by persons discharging managerial responsibilities & persons closely associated with them
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
South African income tax number: 9432434182
(’Mediclinic’, the ‘Company’, or the ’Group’)
21 June 2022
NOTIFICATION: TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES & PERSONS CLOSELY ASSOCIATED WITH THEM
Vesting of awards under the Company's Long-term Incentive (‘LTI’) Plan
This notification sets out details of the vesting of awards over ordinary shares in Mediclinic (’Shares’)
granted to persons discharging managerial responsibilities (’PDMRs’) on 19 June 2019 under the
Company’s LTI Plan (the ‘LTI Plan Awards’), in accordance with the remuneration policy approved by
shareholders in July 2017. These awards were structured as conditional awards vesting on the third
anniversary of the date of grant, subject to the satisfaction of performance conditions over the three-
year period. The LTI Plan Awards of executive directors of Mediclinic are subject to a further two-year
holding period following the third anniversary of the date of grant, with no further performance conditions
attached during the holding period.
On 19 May 2022, the Remuneration Committee approved the vesting of the LTI Plan Awards granted
to the PDMRs listed in the table below at 12.1% of maximum based on the achievement against
performance targets. These awards vested on 20 June 2022 and will be settled in cash based on the
middle-market quotation of a share on 17 June 2022, being 457.40 pence per share. The amount settled
includes the value of dividends attributable to the vested shares during the period between the date of
grant and the date of vesting, being a total of 3.20 pence per share.
Name Director/ Number of Cash settlement
PDMR Shares vested (including
dividend
equivalents)
David John Hadley PDMR 16 621 £76 556
Gert Cornelis Hattingh PDMR 9 857 £45 401
Dr Dirk Cornelius le Roux PDMR 7 739 £35 646
Dr Daniel Liedtke PDMR 15 610 £71 900
Magnus Oetiker PDMR 13 157 £60 601
Koert Hendrik Stefanus Pretorius PDMR 10 760 £49 561
Dr René Toua PDMR 7 739 £35 646
Greg van Wyk PDMR 6 241 £28 746
The LTI Plan Awards granted to Dr Ronnie van der Merwe and Jurgens Myburgh on the same date will
also vest at 12.1% of maximum based on the achievement against performance targets, equating to
45 185 and 24 981 shares, respectively. These awards will also be cash settled (as permitted under the
remuneration policy in place at the time and indicated in the Company’s annual report for the financial
year ended on 31 March 2019), as soon as practicable after vesting on 18 June 2024.
For further information, please refer to page 160 of the Company’s annual report for the financial year
ended 31 March 2022.
The notifications below are made in accordance with Articles 19.1 and 19.3 of the Market Abuse
Regulation.
1. Details of PDMR / person closely associated with them (‘PCA’)
a) Name David John Hadley
2. Reason for the notification
a) Position / status Chief Executive Officer – Mediclinic Middle East
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 16 621
d) Aggregated
information
Aggregated volume 16 621
Price £nil
e) Date of the 20 June 2022
transaction
f) Place of the London Stock Exchange
transaction
1. Details of PDMR / PCA
a) Name Gert Cornelis Hattingh
2. Reason for the notification
a) Position / status Group Chief Governance Officer – Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 9 857
d) Aggregated
information
Aggregated volume 9 857
Price £nil
e) Date of the 20 June 2022
transaction
f) Place of the London Stock Exchange
transaction
1. Details of PDMR / PCA
a) Name Dr Dirk Cornelius le Roux
2. Reason for the notification
a) Position / status Group Chief Information Officer – Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 7 739
d) Aggregated
information
Aggregated volume 7 739
Price £nil
e) Date of the 20 June 2022
transaction
f) Place of the London Stock Exchange
transaction
1. Details of PDMR / PCA
a) Name Dr Daniel Liedtke
2. Reason for the notification
a) Position / status Chief Executive Officer – Hirslanden
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 15 610
d) Aggregated
information
Aggregated volume 15 610
Price £nil
e) Date of the 20 June 2022
transaction
f) Place of the London Stock Exchange
transaction
1. Details of PDMR / PCA
a) Name Magnus Oetiker
2. Reason for the notification
a) Position / status Group Chief Strategy Officer – Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 13 157
d) Aggregated
information
Aggregated volume 13 157
Price £nil
e) Date of the 20 June 2022
transaction
f) Place of the London Stock Exchange
transaction
1. Details of PDMR / PCA
a) Name Koert Hendrik Stefanus Pretorius
2. Reason for the notification
a) Position / status Group Chief Operating Officer – Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 10 760
d) Aggregated
information
Aggregated volume 10 760
Price £nil
e) Date of the 20 June 2022
transaction
f) Place of the London Stock Exchange
transaction
1. Details of PDMR / PCA
a) Name Dr René Toua
2. Reason for the notification
a) Position / status Group Chief Clinical Officer – Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 7 739
d) Aggregated
information
Aggregated volume 7 739
Price £nil
e) Date of the 20 June 2022
transaction
f) Place of the London Stock Exchange
transaction
1. Details of PDMR / PCA
a) Name Greg van Wyk
2. Reason for the notification
a) Position / status Chief Executive Officer – Mediclinic Southern Africa
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 6 241
d) Aggregated
information
Aggregated volume 6 241
Price £nil
e) Date of the 20 June 2022
transaction
f) Place of the London Stock Exchange
transaction
About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in South Africa in
1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.
The Group's core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum
of care in such a way that the Group will be regarded as the most respected and trusted provider of
healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of
its markets.
At 31 March 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health
facilities, 20 day case clinics and 20 outpatient clinics. The Swiss operations included 17 hospitals and
four day case clinics with around 1 900 inpatient beds; Southern Africa operations included 50 hospitals
(three of which in Namibia), five subacute hospitals, two mental health facilities and 14 day case clinics
(four of which operated by Intercare) across South Africa, and around 8 650 inpatient beds; and the
Middle East operated seven hospitals, two day case clinics and 20 outpatient clinics with around 1 000
inpatient beds in the UAE. In addition, under management contract the Middle East will open a 200-bed
hospital in the Kingdom of Saudi Arabia in 2023.
The Company's primary listing is on the London Stock Exchange ('LSE') in the United Kingdom (‘UK’),
with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the UK and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, UK
Website: www.mediclinic.com
Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment
Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Date: 21-06-2022 05:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.